Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
Rhea-AI Summary
Adial Pharmaceuticals (NASDAQ: ADIL) praised bipartisan H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, introduced March 24, 2026 to expand R&D access for veteran health conditions including Alcohol Use Disorder (AUD).
The bill recognizes non‑abstinence recovery outcomes and could support investigational therapies like Adial’s genetically targeted candidate AD04, which targets reductions in heavy drinking days as a clinical endpoint.
Positive
- None.
Negative
- None.
News Market Reaction – ADIL
On the day this news was published, ADIL declined 8.15%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.0% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $232K from the company's valuation, bringing the market cap to $2.61M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ADIL was down 8% with low volume while 2 tracked biotech peers (e.g., AIM, IBO) in momentum scans also moved down (median about -5.6%), pointing to broader sector pressure rather than a purely idiosyncratic move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 06 | Earnings and update | Positive | -7.1% | Reported 2025 results, positive AD04-103 PK, supportive FDA feedback, extended IP. |
| Mar 03 | Partnership framework | Positive | -7.3% | Signed exclusive AD04 collaboration framework with Molteni for European rights. |
| Feb 24 | Nasdaq compliance | Positive | +4.7% | Regained full compliance with Nasdaq minimum bid price listing requirement. |
| Feb 23 | FDA policy highlight | Positive | -4.9% | Highlighted FDA policy that may allow approval with one pivotal trial plus evidence. |
| Feb 17 | Conference presentation | Neutral | -5.3% | Announced CEO presentation and investor meetings at Oppenheimer healthcare conference. |
Recent fundamentally positive updates on AD04, regulatory alignment, and partnerships often coincided with negative price reactions, except for the Nasdaq compliance news.
Over recent months, Adial has focused on advancing AD04 toward Phase 3, improving regulatory alignment, and shoring up its listing status. A collaboration framework with Molteni in Europe, a regained Nasdaq minimum bid price, and constructive FDA policy signals all preceded this announcement recognizing AUD in new federal legislation. The pattern shows multiple clinically and strategically positive milestones with mixed-to-negative price reactions, framing today’s policy-aligned news within an already de‑risked regulatory narrative for AD04.
Regulatory & Risk Context
An effective S-3 shelf dated 2025-12-12 registers up to 13,823,512 shares of common stock for resale upon exercise of Series F warrants. Adial would receive cash only if these warrants are exercised, while the large registered share amount relative to its equity base creates potential dilution and stock overhang.
Market Pulse Summary
The stock moved -8.2% in the session following this news. A negative reaction despite policy support from H.R. 7091 would fit a pattern where positive clinical, regulatory, or partnership updates (e.g., Molteni framework, favorable FDA signals) still saw selling pressure. With shares far below the 200-day MA of $7.55 and an effective shelf registering 13,823,512 shares for resale, overhang and a short interest of 25.12% could amplify downside moves even on seemingly supportive news.
Key Terms
alcohol use disorder medical
aud medical
food & drug administration regulatory
harm reduction medical
substance use disorders medical
sud medical
AI-generated analysis. Not financial advice.
H.R. 7091 Supports Development of Investigational Treatments for Alcohol Use Disorder and Aligns with Evolving Federal Recovery Standards
GLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, bipartisan legislation aimed at expanding research and development of emerging therapies for conditions affecting U.S. veterans, specifically including Alcohol Use Disorder (AUD).
Alcohol Use Disorder remains a significant issue within the veteran population, with nearly
H.R. 7091 specifically includes AUD among the conditions eligible for expanded research and development efforts. The legislation supports investigational pharmaceutical therapies that meet the U.S. Government’s updated definition of recovery, which includes non-abstinence based treatment options. This definition reflects evolving federal policy recognizing harm reduction and reductions in heavy drinking as meaningful clinical outcomes.
Adial’s lead investigational product candidate, AD04, is being developed as a genetically targeted therapy for Alcohol Use Disorder. AD04 follows a non-abstinence based treatment approach and aligns with FDA supported endpoints focused on harm reduction and reduction in heavy drinking days, consistent with direction provided by Congress in the federal Appropriations package.
“We applaud members of Congress for introducing this important bipartisan legislation and for specifically recognizing AUD as a critical issue affecting our nation’s veterans,” said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. “By expanding support for emerging therapies that align with the government’s updated definition of recovery, including non-abstinence treatment options, this bill represents meaningful progress for veterans in need of additional treatment options.”
The bill has been referred to the House Committee on Veterans’ Affairs and reflects bipartisan recognition of the need to advance innovative approaches for Substance Use Disorders (SUD), including Alcohol Use Disorder, which is often underemphasized within broader SUD policy initiatives.
Adial believes that H.R. 7091 reinforces federal support for harm reduction based treatment paradigms and may help advance development efforts for emerging investigational therapies such as AD04.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Adial is currently planning to conduct a new Phase 3 clinical trial program for the treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, with no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding expanding research and development of emerging therapies for conditions affecting U.S. veterans, specifically including AUD, developing AD04 as a genetically targeted therapy for AUD, H.R. 7091 reinforcing federal support for harm reduction based treatment paradigms and helping advance development efforts for emerging investigational therapies such as AD04 and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, including our ability to finalize and enter into a definitive agreement regarding the planned partnership with Molteni, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing as well as the Parties’ ability to enter into a definitive agreement. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
FAQ
What does H.R. 7091 mean for Adial Pharmaceuticals (ADIL) and its AD04 candidate?
How does H.R. 7091 change federal recovery standards for Alcohol Use Disorder relevant to ADIL (ADIL)?
What stage is Adial’s AD04 in and how might the bill affect its development timeline?
Does H.R. 7091 specifically prioritize veterans with Alcohol Use Disorder for investigational therapies?
What is the current legislative status of H.R. 7091 mentioned by Adial (ADIL)?
